{
    "clinical_study": {
        "@rank": "41991", 
        "acronym": "FOP", 
        "biospec_descr": {
            "textblock": "Urine samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect urine samples from patients with fibrodysplasia\n      ossificans progressiva (FOP) for the assessment of biomarkers related to disease, disease\n      progression and for prediction of flare-ups of the disease. Disease related biomarkers in\n      these patients are currently unknown. This study aims to support the development of novel\n      therapy/ies for this disease."
        }, 
        "brief_title": "Urine Sample Collection From FOP Patients", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Fibrodysplasia Ossificans Progressiva", 
        "condition_browse": {
            "mesh_term": "Myositis Ossificans"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients \u2265 5 and \u2264 35 years of age with a diagnosis of FOP.\n\n          -  Physically able to provide first-morning urine sample of at least 30 mL\n\n          -  Able to communicate well with the investigator, to understand and comply with the\n             requirements of the study\n\n          -  About half of the patients enrolled should have a flare-up, which is defined as an\n             acute exacerbation of disease activity characterized by two or more of the following\n             symptoms: pain, swelling, decreased range of motion, impaired function\n\n        Exclusion Criteria:\n\n          -  Diagnosis of diabetes\n\n          -  Diagnosis of other systemic inflammatory disorder (juvenile idiopathic arthritis,\n             systemic lupus erythematosus, etc.)\n\n          -  Diagnosis of cancer other than nonmelanomatous skin cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "5 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Fibrodysplasia Ossificans Progressiva."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066324", 
            "org_study_id": "CPJMR0062203"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Urine Sample Collection From Patients With Fibrodysplasia Ossificans Progressiva (FOP) for Biomarker Analysis", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The objective of this study is to collect urine samples from patients with FOP over a time period covering ideally quiescent disease status and progression through a flare-up for biomarker analysis", 
                "measure": "Analysis of pre-defined biomarker FGF2", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "The objective of this study is to collect urine samples from patients with FOP over a time period covering ideally quiescent disease status and progression through a flare-up for biomarker analysis", 
                "measure": "Analysis of pre-defined biomarker WEGF", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "The objective of this study is to collect urine samples from patients with FOP over a time period covering ideally quiescent disease status and progression through a flare-up for biomarker analysis", 
                "measure": "Analysis of microRNAs", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066324"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}